In clinical practice, maximizing treatment efficacy while minimizing adverse effects is of paramount importance. The idea of precision therapeutics has been strongly advocated in recent years, thanks to rapid technological advancements such as genetic sequencing and molecular targeted drug exploitation. The goal of precision therapeutics is to distinguish illnesses using a wide variety of data, from genomes to digital health measurements, to enable a unique, yet "evidence-based" choice about theranostic (diagnostic and treatment) approaches, rather than grouping patients into a "one size fits all" approach. Emerging roles of theranostic agents in the field of precision medicine have elevated recently, impacting the possible treatment strategies of multiple human diseases, including cancers, neurological diseases and inflammatory diseases. Discovery of novel small molecules, design and synthesis of ubiquitination-mediated protein degradation by proteolysis-targeting chimeras (PROTACs), capable of selectively degrading proteins, and mRNA targeted therapies are just a few to mention here.
Precision therapeutics has also allowed nanocarriers to be used in their delivery, which has evolved nanomedicine. Recent studies showing the use of exosomes and liposomes to deliver precision therapeutics, without showing overt sign of toxicities, have provided additional support to choose the best carriers for delivery of precision therapeutics.
In this Research Topic, we will concentrate on collecting the latest advancements for precision therapeutics across multiple diseases. Also, we highlight the emerging concepts related to the delivery of therapeutics, crucial for the success of precision therapies. We anticipate that our Research Topic will contribute to expanding the research community's knowledge about this recent and rapidly growing field of precision therapeutics, which will surely help manage multiple lethal diseases.
Themes of interest include but are not limited to:
• Discovery of novel small molecules targeting kinases
• Discovery of degraders targeting oncogenic proteins
• Discovery of novel small molecules targeting RNA modifiers
• Emerging advancements in exosomes-based delivery platform
• Emerging advancements in liposome-based delivery platform
• Emerging advancements in Nanotherapeutics
In clinical practice, maximizing treatment efficacy while minimizing adverse effects is of paramount importance. The idea of precision therapeutics has been strongly advocated in recent years, thanks to rapid technological advancements such as genetic sequencing and molecular targeted drug exploitation. The goal of precision therapeutics is to distinguish illnesses using a wide variety of data, from genomes to digital health measurements, to enable a unique, yet "evidence-based" choice about theranostic (diagnostic and treatment) approaches, rather than grouping patients into a "one size fits all" approach. Emerging roles of theranostic agents in the field of precision medicine have elevated recently, impacting the possible treatment strategies of multiple human diseases, including cancers, neurological diseases and inflammatory diseases. Discovery of novel small molecules, design and synthesis of ubiquitination-mediated protein degradation by proteolysis-targeting chimeras (PROTACs), capable of selectively degrading proteins, and mRNA targeted therapies are just a few to mention here.
Precision therapeutics has also allowed nanocarriers to be used in their delivery, which has evolved nanomedicine. Recent studies showing the use of exosomes and liposomes to deliver precision therapeutics, without showing overt sign of toxicities, have provided additional support to choose the best carriers for delivery of precision therapeutics.
In this Research Topic, we will concentrate on collecting the latest advancements for precision therapeutics across multiple diseases. Also, we highlight the emerging concepts related to the delivery of therapeutics, crucial for the success of precision therapies. We anticipate that our Research Topic will contribute to expanding the research community's knowledge about this recent and rapidly growing field of precision therapeutics, which will surely help manage multiple lethal diseases.
Themes of interest include but are not limited to:
• Discovery of novel small molecules targeting kinases
• Discovery of degraders targeting oncogenic proteins
• Discovery of novel small molecules targeting RNA modifiers
• Emerging advancements in exosomes-based delivery platform
• Emerging advancements in liposome-based delivery platform
• Emerging advancements in Nanotherapeutics
